Transformation of primary murine peritoneal mast cells by constitutive KIT activation is accompanied by loss of Cdkn2a/Arf expression

Mast cells (MCs) are immune cells of the myeloid lineage distributed in tissues throughout the body. Phenotypically, they are a heterogeneous group characterized by different protease repertoires stored in secretory granules and differential presence of receptors. To adequately address aspects of MC biology either primary MCs isolated from human or mouse tissue or different human MC lines, like HMC-1.1 and -1.2, or rodent MC lines like L138.8A or RBL-2H3 are frequently used. Nevertheless, cellular systems to study MC functions are very limited. We have generated a murine connective tissue-like MC line, termed PMC-306, derived from primary peritoneal MCs (PMCs), which spontaneously transformed. We analyzed PMC-306 cells regarding MC surface receptor expression, effector functions and respective signaling pathways, and found that the cells reacted very similar to primary wildtype (WT) PMCs. In this regard, stimulation with MAS-related G-protein-coupled receptor member B2 (MRGPRB2) ligands induced respective signaling and effector functions. Furthermore, PMC-306 cells revealed significantly accelerated cell cycle progression, which however was still dependent on interleukine 3 (IL-3) and stem cell factor (SCF). Phenotypically, PMC-306 cells adopted an immature connective tissue-like MCs appearance. The observation of cellular transformation was accompanied by the loss of Cdkn2a and Arf expression, which are both described as critical cell cycle regulators. The loss of Cdkn2a and Arf expression could be mimicked in primary bone marrow-derived mast cells (BMMCs) by sustained SCF supplementation strongly arguing for an involvement of KIT activation in the regulation of Cdkn2a/Arf expression. Hence, this new cell line might be a useful tool to study further aspects of PMC function and to address tumorigenic processes associated with MC leukemia.

[1]  Helen K. Matthews,et al.  Cell cycle control in cancer , 2021, Nature Reviews Molecular Cell Biology.

[2]  Philip A. Ewels,et al.  FelixKrueger/TrimGalore: v0.6.7 - DOI via Zenodo , 2021 .

[3]  R. Płoski,et al.  Higher Mutation Burden in High Proliferation Compartments of Heterogeneous Melanoma Tumors , 2021, International journal of molecular sciences.

[4]  A. S. St. John,et al.  Protective and pathogenic roles for mast cells during viral infections , 2020, Current Opinion in Immunology.

[5]  M. Tsai,et al.  Mast Cells in Inflammation and Disease: Recent Progress and Ongoing Concerns. , 2020, Annual review of immunology.

[6]  Philip A. Ewels,et al.  The nf-core framework for community-curated bioinformatics pipelines , 2020, Nature Biotechnology.

[7]  J. Krijgsveld,et al.  Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation. , 2020, Immunity.

[8]  R. Jessberger,et al.  Regulation of the pleiotropic effects of tissue-resident mast cells. , 2019, The Journal of allergy and clinical immunology.

[9]  S. Galli,et al.  Mast cells are critical for controlling the bacterial burden and the healing of infected wounds , 2019, Proceedings of the National Academy of Sciences.

[10]  S. Snyder,et al.  A Connective Tissue Mast-Cell-Specific Receptor Detects Bacterial Quorum-Sensing Molecules and Mediates Antibacterial Immunity. , 2019, Cell host & microbe.

[11]  Ali M. Gabali,et al.  Mast cell leukemia and hemophagocytosis in a patient with myelodysplastic syndrome. , 2019, Blood.

[12]  Xinzhong Dong,et al.  A Mast-Cell-Specific Receptor Mediates Neurogenic Inflammation and Pain , 2019, Neuron.

[13]  Aída Castillo-Alvarez,et al.  Cell proliferation and inhibition of apoptosis are related to c-Kit activation in leukaemic lymphoblasts , 2018, Hematology.

[14]  Paolo Di Tommaso,et al.  Nextflow enables reproducible computational workflows , 2017, Nature Biotechnology.

[15]  J. Henderson,et al.  Defective bone repair in mast cell-deficient Cpa3Cre/+ mice , 2017, PloS one.

[16]  G. Nilsson,et al.  Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. , 2017, Cancer research.

[17]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[18]  Xinzhong Dong,et al.  Different activation signals induce distinct mast cell degranulation strategies. , 2016, The Journal of clinical investigation.

[19]  M. Huber,et al.  Isolation of Mature (Peritoneum-Derived) Mast Cells and Immature (Bone Marrow-Derived) Mast Cell Precursors from Mice , 2016, PloS one.

[20]  Xuan Zhou,et al.  Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia , 2016, Journal of Hematology & Oncology.

[21]  Christopher P. Johnson,et al.  Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling. , 2016, The American journal of pathology.

[22]  B. Engelward,et al.  Inflammation-Induced Cell Proliferation Potentiates DNA Damage-Induced Mutations In Vivo , 2015, PLoS genetics.

[23]  Xinzhong Dong,et al.  Identification of a mast cell specific receptor crucial for pseudo-allergic drug reactions , 2014, Nature.

[24]  C. Nogués,et al.  Chromosome Instability in mouse Embryonic Stem Cells , 2014, Scientific Reports.

[25]  G. Pejler,et al.  Mast cell secretory granules: armed for battle , 2014, Nature Reviews Immunology.

[26]  Dirk Merkel,et al.  Docker: lightweight Linux containers for consistent development and deployment , 2014 .

[27]  S. Herms,et al.  The transcriptome of the human mast cell leukemia cells HMC-1.2: an approach to identify specific changes in the gene expression profile in KitD816V systemic mastocytosis , 2013, Immunologic research.

[28]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[29]  M. Huber.  Activation/Inhibition of mast cells by supra-optimal antigen concentrations , 2013, Cell Communication and Signaling.

[30]  J. Mulvihill,et al.  Trisomy 8: a common finding in mouse embryonic stem (ES) cell lines , 2013, Molecular Cytogenetics.

[31]  D. Housman,et al.  Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation. , 2011, Cancer research.

[32]  K. Austen,et al.  Protease phenotype of constitutive connective tissue and of induced mucosal mast cells in mice is regulated by the tissue , 2011, Proceedings of the National Academy of Sciences.

[33]  J. Steinke,et al.  Characterization of a novel human mast cell line that responds to stem cell factor and expresses functional FcεRI. , 2011, The Journal of allergy and clinical immunology.

[34]  M. Tsai,et al.  Mast cells in allergy and infection: Versatile effector and regulatory cells in innate and adaptive immunity , 2010, European journal of immunology.

[35]  Thomas Kamradt,et al.  The receptor tyrosine kinase c-Kit controls IL-33 receptor signaling in mast cells. , 2010, Blood.

[36]  E. Passante,et al.  The RBL-2H3 cell line: its provenance and suitability as a model for the mast cell , 2009, Inflammation Research.

[37]  D. Metcalfe.  Mast cells and mastocytosis. , 2008, Blood.

[38]  Mozaffarul Islam,et al.  A new fixation procedure for improved quality G‐bands in routine cytogenetic work , 2008 .

[39]  Stephen J Galli,et al.  Mast cell–derived interleukin 10 limits skin pathology in contact dermatitis and chronic irradiation with ultraviolet B , 2007, Nature Immunology.

[40]  K. Roget,et al.  Peritoneal Cell-Derived Mast Cells: An In Vitro Model of Mature Serosal-Type Mouse Mast Cells1 , 2007, The Journal of Immunology.

[41]  M. Maurer,et al.  Mast cells--key effector cells in immune responses. , 2007, Trends in immunology.

[42]  S. Bischoff.  Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data , 2007, Nature Reviews Immunology.

[43]  D. Carrasco,et al.  The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans. , 2006, Cancer cell.

[44]  S. Takai,et al.  Expression of chymase‐positive cells in gastric cancer and its correlation with the angiogenesis , 2006, Journal of surgical oncology.

[45]  N. Sharpless,et al.  INK4a/ARF: a multifunctional tumor suppressor locus. , 2005, Mutation research.

[46]  D. Warburton,et al.  The role of trypsin in the pre-treatment of chromosomes for giemsa banding , 1976, Human Genetics.

[47]  Y. Kitamura,et al.  What is the physiological function of mast cells? , 2003, Experimental dermatology.

[48]  D. Metcalfe,et al.  Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI. , 2003, Leukemia research.

[49]  G. Nilsson,et al.  Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c‐kit proto‐oncogene , 2003, Immunology.

[50]  F. McCormick,et al.  The RB and p53 pathways in cancer. , 2002, Cancer cell.

[51]  F. Apiou,et al.  Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors , 2002, Oncogene.

[52]  Charles J. Sherr,et al.  The INK4a/ARF network in tumour suppression , 2001, Nature Reviews Molecular Cell Biology.

[53]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[54]  G. Nilsson,et al.  Murine mast cell lines as indicators of early events in mast cell and basophil development , 2000, European journal of immunology.

[55]  M. Löhning,et al.  Reversible expression of tryptases in continuous L138.8A mast cells , 2000, European journal of immunology.

[56]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[57]  Charles J. Sherr,et al.  Nucleolar Arf sequesters Mdm2 and activates p53 , 1999, Nature Cell Biology.

[58]  M. Serrano,et al.  p19ARF links the tumour suppressor p53 to Ras , 1998, Nature.

[59]  J L Cleveland,et al.  Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. , 1998, Genes & development.

[60]  S. Lowe,et al.  E1A signaling to p53 involves the p19(ARF) tumor suppressor. , 1998, Genes & development.

[61]  Richard A. Ashmun,et al.  Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.

[62]  J. Nevins,et al.  Distinct roles for E2F proteins in cell growth control and apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Yamamoto,et al.  Impaired tyrosine phosphorylation and Ca2+ mobilization, but not degranulation, in lyn-deficient bone marrow-derived mast cells. , 1997, Journal of immunology.

[64]  S. Abraham,et al.  Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-α , 1996, Nature.

[65]  L. Ashman,et al.  Internalization of Kit together with stem cell factor on human fetal liver-derived mast cells: new protein and RNA synthesis are required for reappearance of Kit. , 1996, Journal of immunology.

[66]  W. Hiddemann,et al.  Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. , 1995, Blood.

[67]  G. Krystal,et al.  Multiple cytokines stimulate the binding of a common 145-kilodalton protein to Shc at the Grb2 recognition site of Shc , 1994, Molecular and cellular biology.

[68]  D. Friend,et al.  Mouse bone marrow-derived mast cells (mBMMC) obtained in vitro from mice that are mast cell-deficient in vivo express the same panel of granule proteases as mBMMC and serosal mast cells from their normal littermates , 1994, The Journal of experimental medicine.

[69]  G. Nilsson,et al.  Phenotypic Characterization of the Human Mast‐Cell Line HMC‐1 , 1994, Scandinavian journal of immunology.

[70]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[71]  L. Ashman,et al.  Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. , 1993, The Journal of clinical investigation.

[72]  H. Karasuyama,et al.  Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors , 1988, European journal of immunology.

[73]  G. Dewald,et al.  Establishment of an immature mast cell line from a patient with mast cell leukemia. , 1988, Leukemia research.

[74]  C. Heusser,et al.  Spontaneous, in vitro, malignant transformation of a basophil/mast cell line. , 1983, Differentiation; research in biological diversity.

[75]  R. Siraganian,et al.  IgE‐induced histamine release from rat basophilic leukemia cell lines: isolation of releasing and nonreleasing clones , 1981, European journal of immunology.

[76]  A. Henderson,et al.  International Standing Committee on Human Cytogenetic Nomenclature , 1976 .

[77]  E. Eccleston,et al.  Basophilic leukaemia in the albino rat and a demonstration of the basopoietin. , 1973, Nature: New biology.